



2023 Annual Meeting Planning Committee (AMPC) Disclosures

The AMPC provides oversight and guidance on all educational activities related to the ACR Annual Meeting. Because it is not always clear what content or topic will be discussed, committee members are asked to disclose all financial relationships. Recusal is the primary mechanism for resolution. However, by the nature of committee work, the peer process also plays a role in ensuring balance.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.

The following types of relationships may be deemed relevant include:

1. Advisor or Review Panel Member
2. Consultant
3. Employee
4. Officer or Board Member
5. Grant/Research Support
6. Speaker/Honoraria (includes speakers bureau, symposia, and expert witness)
7. Independent Contractor
8. Ownership Interest
9. Royalties
10. Intellectual Property/Patents
11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
12. Other Financial or Material Support

All of the relevant financial relationships listed for the meeting faculty have been mitigated.

Iannis Adamopoulos, PhD

Disclosure(s): No financial relationships with ineligible companies to disclose

Brittany Adler, MD

Disclosure(s): No financial relationships with ineligible companies to disclose

Salahuddin Ahmed, PhD, MSc

Disclosure(s): No financial relationships with ineligible companies to disclose

Anca Askanase, MD, MPH

Disclosure(s): Amgen: Data Safety Monitoring Board (Ongoing); AstraZeneca: 1 (Ongoing); Bristol-Myers Squibb(BMS): Clinical Trial Steering Committee (Ongoing); Genentech: Investigator in clinical trial (Ongoing); GlaxoSmithKlein(GSK): 1 (Ongoing); Idorsia: Lead PI for clinical trial (Ongoing); Sanofi: Lead PI clinical trial (Ongoing)

Janet Bahr, NP

Disclosure(s): No financial relationships with ineligible companies to disclose

April Barnado, MD, MSc

Disclosure(s): No financial relationships with ineligible companies to disclose

Betsy Barnes, PhD

Disclosure(s): No financial relationships with ineligible companies to disclose

Sarah Bayefsky, MD

Disclosure(s): No financial relationships with ineligible companies to disclose

Elana Bernstein, MD, MSc

Disclosure(s): Boehringer-Ingelheim: 1 (Ongoing), 2 (Ongoing), 5 (Ongoing); Kadmon: 5 (Ongoing); Pfizer: 5 (Ongoing)

Matthew Bunyard, MD, RhMSUS

Disclosure(s): No financial relationships with ineligible companies to disclose

Priscilla Calvache, LCSW, MSW

Disclosure(s): No financial relationships with ineligible companies to disclose

Laura Cappelli, MD

Disclosure(s): Bristol-Myers Squibb(BMS): 2 (Ongoing), 5 (Ongoing); Mallinckrodt: 1 (Terminated, November 15, 2021); Tremereau Pharmaceuticals: 2 (Terminated, May 10, 2022)

Aimee Chen-Wiener, MSN, APRN

Disclosure(s): No financial relationships with ineligible companies to disclose

Anne Davidson, MBBS, FRACP

Disclosure(s): No financial relationships with ineligible companies to disclose

Elaine Flanagan, MD, RhMSUS

Disclosure(s): No financial relationships with ineligible companies to disclose

Elizabeth Frame, MD

Disclosure(s): No financial relationships with ineligible companies to disclose

Tracy Frech, MD, MS

Disclosure(s): No financial relationships with ineligible companies to disclose

Sarah Goglin, MD

Disclosure(s): No financial relationships with ineligible companies to disclose

Rebecca Grainger, PhD, FRACP, MBChB

Disclosure(s): AbbVie/Abbott: 1 (Ongoing), 6 (Ongoing); Novartis: 1 (Terminated, September 30, 2022), 6 (Terminated, September 30, 2022)

Jaime Guzman, MD, MSc

Disclosure(s): No financial relationships with ineligible companies to disclose

Jonathan Hausmann, MD

Disclosure(s): Fresenius Kabi: 2 (Terminated); Novartis: 2 (Ongoing)

Joseph Huffstutter, MD, FACP, FACR

Disclosure(s): Eli Lilly: 6 (Ongoing); GlaxoSmithKlein(GSK): 5 (Ongoing), 6 (Ongoing); Janssen: 6 (Ongoing); UCB: 6 (Ongoing)

Mary Beth Humphrey, MD, PhD

Disclosure(s): No financial relationships with ineligible companies to disclose

Rumey Ishizawar, MD, PhD

Disclosure(s): No financial relationships with ineligible companies to disclose

Scott Jamieson, MS

Disclosure(s): No financial relationships with ineligible companies to disclose

Matlock Jeffries, MD, FACP, FACR

Disclosure(s): No financial relationships with ineligible companies to disclose

April Jorge, MD

Disclosure(s): No financial relationships with ineligible companies to disclose

Diane Kamen, MD, MS

Disclosure(s): Alpine Immune Sciences: 1 (Ongoing); Equillum: 1 (Ongoing)

Guy Katz, MD

Disclosure(s): No financial relationships with ineligible companies to disclose

Salahuddin Kazi, MD

Disclosure(s): No financial relationships with ineligible companies to disclose

Puja Khanna, MD, MPH

Disclosure(s): Arthroxi: 5 (Ongoing); Dyve: 5 (Ongoing); Horizon: 2 (Ongoing); Selecta: 5 (Ongoing)

Hanna Kim, MD, MS

Disclosure(s): Eli Lilly and Company: CRADA (trial support including drug) (Ongoing)

Curry Koenig, MD, MS

Disclosure(s): chemocentryx: 1 (Terminated, May 31, 2022), 6 (Terminated, May 31, 2022)

Minna Kohler, MD, RhMSUS

Disclosure(s): No relevant disclosure to display

Sharon Kolasinski, MD

Disclosure(s): No financial relationships with ineligible companies to disclose

Jason Kolfenbach, MD

Disclosure(s): No financial relationships with ineligible companies to disclose

Benjamin Korman, MD

Disclosure(s): Teneofour, Inc: 2 (Terminated, October 1, 2022)

Nancy Lane, MD

Disclosure(s): Amgen: 2 (Ongoing)

Sivia Lapidus, MD

Disclosure(s): No financial relationships with ineligible companies to disclose

Kara Long, PA-C

Disclosure(s): No financial relationships with ineligible companies to disclose

Christian Lood, PhD

Disclosure(s): No relevant disclosure to display

Eyal Muscal, MD, MS

Disclosure(s): No relevant disclosure to display

Bernard Ng, MBBS, MSc, MMed

Disclosure(s): No financial relationships with ineligible companies to disclose

Uyen-Sa Nguyen

Disclosure(s): No financial relationships with ineligible companies to disclose

Julie Paik, MD, MHS

Disclosure(s): No financial relationships with ineligible companies to disclose

Christopher Palma, MD, RhMSUS

Disclosure(s): No financial relationships with ineligible companies to disclose

Janet Pope, MD, FRCPC, MPH

Disclosure(s): AbbVie/Abbott: 2 (Ongoing), 5 (Ongoing); Amgen: 2 (Ongoing); AstraZeneca: 2 (Ongoing); Boehringer Ingelheim: 1 (Ongoing), 2 (Ongoing), 6 (Ongoing); Eli Lilly: 2 (Ongoing), 5 (Ongoing); Fresenius Kabi: 2 (Ongoing); GlaxoSmithKlein(GSK): 2 (Ongoing); Janssen: 2 (Ongoing); Mallinckrodt: 2 (Ongoing); Novartis: 2 (Ongoing); Organon: 2 (Ongoing); Pfizer: 2 (Ongoing); Sandoz: 2 (Ongoing); Viatris: 2 (Ongoing)

Roneka Ravenell, MD

Disclosure(s): No financial relationships with ineligible companies to disclose

Priya Reddy, MD

Disclosure(s): Abbvie, UCB: 2 (Ongoing), 6 (Ongoing); Amgen, Horizon: 2 (Ongoing), 6 (Ongoing); Exagen: 2 (Ongoing), 6 (Ongoing); Janssen: 2 (Terminated, February 3, 2023), 6 (Terminated, February 3, 2023); Novartis: 2 (Terminated, February 3, 2023); Pfizer: 2 (Terminated, February 3, 2023), 6 (Terminated, February 3, 2023); Sanofi: 2 (Terminated, February 3, 2023); Scipher: 2 (Ongoing)

Beth Resman-Targoff, PharmD, FCCP

Disclosure(s): No financial relationships with ineligible companies to disclose

Noelle A. Rolle, MBBS

Disclosure(s): GlaxoSmithKlein(GSK): 2 (Ongoing)

Jillian Rose-Smith, PhD, MPH, MSW

Disclosure(s): No financial relationships with ineligible companies to disclose

Natasha Ruth, MD, MS

Disclosure(s): No financial relationships with ineligible companies to disclose

Vaneet Sandhu, MD, MS, RhMSUS

Disclosure(s): No relevant disclosure to display

Julie Schwartzman-Morris, MD, MS

Disclosure(s): No financial relationships with ineligible companies to disclose

Susan Sheno, MS, MBBS, RhMSUS

Disclosure(s): No financial relationships with ineligible companies to disclose

Namrata Singh, MD, MSc

Disclosure(s): Pfizer: 1 (Terminated, April 29, 2022)

Carolyn Smith, MSN, CPNP

Disclosure(s): No financial relationships with ineligible companies to disclose

Joshua Stefanik, PhD, PT

Disclosure(s): No financial relationships with ineligible companies to disclose

Teresa Tarrant, MD

Disclosure(s): Chiesi: 2 (Ongoing), 5 (Ongoing); Viela Bio: 5 (Ongoing); X4 Pharmaceuticals: 2 (Ongoing), 5 (Ongoing)

Michael Toprover, MD

Disclosure(s): No relevant disclosure to display

Elizabeth Volkmann, MD, MS

Disclosure(s): Boehringer-Ingelheim: 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); GlaxoSmithKlein(GSK): 2 (Ongoing); Horizon: 5 (Ongoing); Kadmon: 5 (Ongoing); Prometheus: 5 (Ongoing); Roche: 2 (Ongoing)